No Data
No Data
Corbus Outlines Phase 1 Results From ADC Trial for Bladder, Cervical Cancers
Astellas Zolbetuximab Resubmission Accepted by FDA
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average rebounded slightly for the first time in 4 days, and Fast Rite boosted by about 41 yen per brand
The number of gains and falls of the Nikkei Average constituent stocks at the time of closing 31 days ago was 2 stocks unchanged: 177 stocks with price increases and 46 stocks with price drops. The Nikkei Average rebounded for the first time in 4 business days. The front-end transaction was closed at 38119.96 yen (estimated volume of 750 million shares), which was 65.83 yen higher (+0.17%) compared to the previous day. The US stock market continued to decline on the 30th. The Dow average depreciated by $330.06 (-0.86%) at $38111.48, and the Nasdaq depreciated 183.50 points (-1.08%) by 1
Astellas (ALPMY.US) CD3/CLDN18.2 dual antibody initiated clinical trial in China
On May 30, according to the CDE clinical trial registration and information disclosure platform, Astellas (ALPMY.US) CD3/Cldn18.2 double antibody ASP2138 initiated phase I/b research in China.
List of Unrivaled Stocks (Part 2) [Ichimoku Equilibrium Chart/Kumoku Stock List]
○List of Unbroken Stocks Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime <1379> Hokuto 1822 1832.75 1853.5 <1433> Vestella 946 955.75 1037.5 <2440> Gurunavi 295 316.5 298.5 <2685>
Seventh Annual TGaS Advisors Best of Benchmark Award Winners Announced
AbbVie, Astellas Pharma Inc., AstraZeneca, Incyte, Eli Lilly and Company and Novo Nordisk Teams Take Home Trophies for Operational ExcellenceWALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a l
No Data